TY - JOUR A1 - Weigel, Tobias A1 - Malkmus, Christoph A1 - Weigel, Verena A1 - Wußmann, Maximiliane A1 - Berger, Constantin A1 - Brennecke, Julian A1 - Groeber‐Becker, Florian A1 - Hansmann, Jan T1 - Fully Synthetic 3D Fibrous Scaffolds for Stromal Tissues—Replacement of Animal‐Derived Scaffold Materials Demonstrated by Multilayered Skin JF - Advanced Materials N2 - The extracellular matrix (ECM) of soft tissues in vivo has remarkable biological and structural properties. Thereby, the ECM provides mechanical stability while it still can be rearranged via cellular remodeling during tissue maturation or healing processes. However, modern synthetic alternatives fail to provide these key features among basic properties. Synthetic matrices are usually completely degraded or are inert regarding cellular remodeling. Based on a refined electrospinning process, a method is developed to generate synthetic scaffolds with highly porous fibrous structures and enhanced fiber‐to‐fiber distances. Since this approach allows for cell migration, matrix remodeling, and ECM synthesis, the scaffold provides an ideal platform for the generation of soft tissue equivalents. Using this matrix, an electrospun‐based multilayered skin equivalent composed of a stratified epidermis, a dermal compartment, and a subcutis is able to be generated without the use of animal matrix components. The extension of classical dense electrospun scaffolds with high porosities and motile fibers generates a fully synthetic and defined alternative to collagen‐gel‐based tissue models and is a promising system for the construction of tissue equivalents as in vitro models or in vivo implants. KW - 3D scaffolds KW - electrospinning KW - highly porous materials KW - multilayered skin KW - stromal tissues Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-276403 VL - 34 IS - 10 ER - TY - JOUR A1 - Karl, Franziska A1 - Wußmann, Maximiliane A1 - Kreß, Luisa A1 - Malzacher, Tobias A1 - Fey, Phillip A1 - Groeber‐Becker, Florian A1 - Üçeyler, Nurcan T1 - Patient‐derived in vitro skin models for investigation of small fiber pathology JF - Annals of Clinical and Translational Neurology N2 - Objective To establish individually expandable primary fibroblast and keratinocyte cultures from 3‐mm skin punch biopsies for patient‐derived in vitro skin models to investigate of small fiber pathology. Methods We obtained 6‐mm skin punch biopsies from the calf of two patients with small fiber neuropathy (SFN) and two healthy controls. One half (3 mm) was used for diagnostic intraepidermal nerve fiber density (IENFD). From the second half, we isolated and cultured fibroblasts and keratinocytes. Cells were used to generate patient‐derived full‐thickness three‐dimensional (3D) skin models containing a dermal and epidermal component. Cells and skin models were characterized morphologically, immunocyto‐ and ‐histochemically (vimentin, cytokeratin (CK)‐10, CK 14, ki67, collagen1, and procollagen), and by electrical impedance. Results Distal IENFD was reduced in the SFN patients (2 fibers/mm each), while IENFD was normal in the controls (8 fibers/mm, 7 fibers/mm). Two‐dimensional (2D) cultured skin cells showed normal morphology, adequate viability, and proliferation, and expressed cell‐specific markers without relevant difference between SFN patient and healthy control. Using 2D cultured fibroblasts and keratinocytes, we obtained subject‐derived 3D skin models. Morphology of the 3D model was analogous to the respective skin biopsy specimens. Both, the dermal and the epidermal layer carried cell‐specific markers and showed a homogenous expression of extracellular matrix proteins. Interpretation Our protocol allows the generation of disease‐specific 2D and 3D skin models, which can be used to investigate the cross‐talk between skin cells and sensory neurons in small fiber pathology. KW - neurology Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-201649 VL - 6 IS - 9 ER - TY - JOUR A1 - Wußmann, Maximiliane A1 - Groeber-Becker, Florian Kai A1 - Riedl, Sabrina A1 - Alihodzic, Dina A1 - Padaric, Daniel A1 - Gerlitz, Lisa A1 - Stallinger, Alexander A1 - Liegl-Atzwanger, Bernadette A1 - Zweytick, Dagmar A1 - Rinner, Beate T1 - In model, in vitro and in vivo killing efficacy of antitumor peptide RDP22 on MUG-Mel2, a patient derived cell line of an aggressive melanoma metastasis JF - Biomedicines N2 - The host defense derived peptide was assessed in different model systems with increasing complexity employing the highly aggressive NRAS mutated melanoma metastases cell line MUG-Mel2. Amongst others, fluorescence microscopy and spectroscopy, as well as cell death studies were applied for liposomal, 2D and 3D in vitro models including tumor spheroids without or within skin models and in vivo mouse xenografts. Summarized, MUG-Mel2 cells were shown to significantly expose the negatively charged lipid phosphatidylserine on their plasma membranes, showing they are successfully targeted by RDP22. The peptide was able to induce cell death in MUG-Mel2 2D and 3D cultures, where it was able to kill tumor cells even inside the core of tumor spheroids or inside a melanoma organotypic model. In vitro studies indicated cell death by apoptosis upon peptide treatment with an LC\(_{50}\) of 8.5 µM and seven-fold specificity for the melanoma cell line MUG-Mel2 over normal dermal fibroblasts. In vivo studies in mice xenografts revealed effective tumor regression upon intratumoral peptide injection, indicated by the strong clearance of pigmented tumor cells and tremendous reduction in tumor size and proliferation, which was determined histologically. The peptide RDP22 has clearly shown high potential against the melanoma cell line MUG-Mel2 in vitro and in vivo. KW - melanoma metastases KW - NRAS mutation KW - antitumor peptide KW - tumor model systems KW - phosphatidylserine Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-297525 SN - 2227-9059 VL - 10 IS - 11 ER - TY - THES A1 - Wußmann, Maximiliane T1 - Humane organotypische 3D Modelle des Malignen Melanoms als in vitro Testsystem für die Bewertung der Wirksamkeit von anti-Tumor Therapeutika T1 - Human organotypic 3D models of malignant melanoma as an in vitro test system to evaluate the efficacy of anti-tumor therapeutics N2 - Das maligne Melanom, eine der seltensten, aber gleichzeitig auch die tödlichste dermatologische Malignität, gekennzeichnet durch die Neigung zu einer frühen Metastasierung sowie die rasche Entwicklung von Therapieresistenzen, zählt zu den Tumorentitäten mit dem höchsten Anstieg der Inzidenz weltweit. Mausmodelle werden häufig verwendet, um die Melanomagenese zu erforschen und neue effektive therapeutische Strategien zu entwickeln, spiegeln die menschliche Physiologie allerdings nur unzureichend wider. In zweidimensionalen (2D) Zellkulturen mangelt es dagegen an wichtigen Komponenten der Mikroumgebung des Tumors und dem dreidimensionalen Gewebekontext. Um dieses Manko zu beheben und die Entwicklung von auf den Menschen übertragbaren Tumormodellen in der onkologischen Forschung voranzutreiben, wurde als Alternative zu Zellkulturen und Tierversuchen humane organotypische dreidimensionale (3D) Melanom-Modelle als in vitro Testsystem für die Bewertung der Wirksamkeit von anti-Tumor Therapeutika entwickelt. Im Zuge dieser Arbeit konnte das in vitro Melanom-Modell entscheidend weiterentwickelt werden. So konnten Modelle unterschiedlichster Komplexität etabliert werden, wobei abhängig von der Fragestellung einfachere epidermale bis hin zu unterschiedlich komplexen Vollhautmodellen Anwendung finden. Durch Simulation der Tumor-Mikroumgebung eignen sich diese zur präklinischen Validierung neuer Tumor-Therapeutika, sowie der Erforschung pathologischer Vorgänge, von der Tumor-Formierung bis zur Metastasierung. Zudem konnten erfolgreich unterschiedlichste humane Melanomzelllinien ins Modell integriert werden; dadurch, dass sich diese durch ihre Treibermutationen, die zur Krankheitsentstehung beitragen, unterscheiden, stellen sie unterschiedliche Ansprüche an potentielle therapeutische Angriffspunkte und ermöglichen das Widerspiegeln vieler Melanom-Subtypen im Modell. Ferner ist es möglich, verschiedene Stadien der Tumor-Entwicklung über die Zugabe von Melanomzellen in Einzelsuspension bzw. von Melanom-Sphäroiden widerzuspiegeln. Es konnte für bestimmte Therapie-Ansätze, wie zielgerichtete Therapien, z.B. die Gabe von sich in der Klinik im Einsatz befindlicher BRAF-/MEK-Inhibitoren, gezeigt werden, dass sich die etablierten Modelle hervorragend als präklinische Testsysteme zur Wirksamkeitsbewertung eignen. Zudem bieten sich einzigartige Möglichkeiten, um die Interaktion humaner Tumorzellen und gesunder Zellen in einem Gewebeverband zu untersuchen. Ferner konnten drei neue technische Analyse-Verfahren zur nicht-invasiven Detektion der Tumor- Pro- und Regression, Beurteilung der Wirksamkeit von potenziellen Anti-Tumor-Therapien sowie der Evaluierung des Tumor-Metabolismusses implementiert werden. Perspektivisch ermöglichen immun-kompetente Melanom-Modelle die Austestung neuer Immun- und Zelltherapien in einem voll humanen System; gleichzeitig leisten die etablierten Modelle einen signifikanten Beitrag zur Reduktion von Tierexperimenten. N2 - Malignant melanoma, one of the rarest but also the most lethal dermatological malignancies, characterized by a propensity for early metastasis as well as the rapid development of therapy resistance, is among the tumor entities with the highest increase in incidence worldwide. Mouse models are widely used to study melanomagenesis and develop new effective therapeutic strategies, but do not adequately reflect human physiology. In contrast, twodimensional (2D) cell cultures lack important components of the tumor microenvironment and three-dimensional tissue context. To address this shortcoming and to advance the development of human-transferable tumor models in oncology research, human organotypic three-dimensional (3D) models of malignant melanoma were developed as an alternative to cell cultures and animal experiments as an in vitro test system for evaluating the efficacy of anti-tumor therapeutics. In the course of this work, the in vitro melanoma model could be significantly further developed. Thus, melanoma models of different complexity could be established, with simpler epidermal to differently complex full skin models being applied, depending on the research question. By simulating the tumor microenvironment, these are suitable for the preclinical validation of new tumor therapeutics, as well as the study of pathological processes, from tumor shaping to metastasis. In addition, a wide variety of human melanoma cell lines have been successfully integrated into the model; by differing in their driver mutations that contribute to disease development, they pose different requirements for potential therapeutic targets and allow many melanoma subtypes to be reflected in the model. Furthermore, it is possible to reflect different stages of tumor development via the addition of melanoma cells in single suspension or melanoma spheroids. For certain therapeutic approaches in malignant melanoma, such as targeted therapies, e.g. the administration of BRAF/MEK inhibitors currently in use in the clinic, it could be shown that the established models are excellently suited as preclinical test systems for efficacy evaluation. In addition, unique opportunities are provided to study the interaction of human tumor cells and healthy cells in a tissue composite. Furthermore, three new technical analysis methods for non-invasive detection of tumor progression and regression, assessment of efficacy of potential anti-tumor therapies, and evaluation of tumor metabolism could be implemented. In perspective, immune-competent melanoma models enable the testing of new immune and cell therapies in a fully human system; at the same time, the established models contribute significantly to the reduction of animal experiments. KW - Melanom KW - In vitro KW - anti-Tumor Therapeutika KW - Wirksamkeitsbewertung KW - 3D Modell KW - Dreidimensionales Modell Y1 - 2024 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-361005 ER -